Literature DB >> 3975725

Cyclophosphamide-associated hepatotoxicity.

J W Goldberg, M D Lidsky.   

Abstract

Cyclophosphamide, a potent alkylating agent, is effective therapy for some rheumatic diseases. Despite primary hepatic activation of the drug, hepatic toxicity has been reported only in one case. We have reported two episodes of hepatic dysfunction associated with oral cyclophosphamide administration in patients with systemic rheumatic diseases.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3975725     DOI： 10.1097/00007611-198502000-00034

Source DB:  PubMed          Journal:  South Med J        ISSN： 0038-4348            Impact factor:   0.954


  8 in total

Review 1.  Dose adaptation of antineoplastic drugs in patients with liver disease.

Authors:  Lydia Tchambaz; Chantal Schlatter; Max Jakob; Anita Krähenbühl; Peter Wolf; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

2.  Acute icteric hepatitis induced by a short course of low-dose cyclophosphamide in a patient with lupus nephritis.

Authors:  Luigi Muratori; Rodolfo Ferrari; Paolo Muratori; Alessandro Granito; Francesco B Bianchi
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

Review 3.  Challenge of liver disease in systemic lupus erythematosus: Clues for diagnosis and hints for pathogenesis.

Authors:  Fernando Bessone; Natalia Poles; Marcelo G Roma
Journal:  World J Hepatol       Date:  2014-06-27

4.  Long-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis.

Authors:  Srinevas K Reddy; Colleen Reilly; Min Zhan; Ayse L Mindikoglu; Yixing Jiang; Barton F Lane; H Richard Alexander; William J Culpepper; Samer S El-Kamary
Journal:  Med Oncol       Date:  2014-05-06       Impact factor: 3.064

5.  Cyclophosphamide and fludarabine monophosphate dose optimization for the non-myeloablative condition in non-human primates to induce transient mixed chimerism via bone marrow transplantation.

Authors:  Yeongbeen Kwon; Kyo Won Lee; Hyojun Park; Jin Kyung Son; JongHyun Lee; Chan Woo Cho; Ghee Young Kwon; Jae Berm Park; Sung Joo Kim
Journal:  Am J Transl Res       Date:  2019-10-15       Impact factor: 4.060

6.  Protective effect of centella triterpene saponins against cyclophosphamide-induced immune and hepatic system dysfunction in rats: its possible mechanisms of action.

Authors:  Pragathi Duggina; Chandra Mouli Kalla; Seshadri Reddy Varikasuvu; Suman Bukke; Vijaya Tartte
Journal:  J Physiol Biochem       Date:  2015-07-14       Impact factor: 4.158

7.  Reversible hepatic dysfunction in association with cyclophosphamide therapy.

Authors:  D V Milford; N Butler; R Clarke; J Vaid
Journal:  Eur J Pediatr       Date:  1995-05       Impact factor: 3.183

8.  Peroxisome Proliferator Activator Receptor (PPAR)- γ Ligand, but Not PPAR- α , Ameliorates Cyclophosphamide-Induced Oxidative Stress and Inflammation in Rat Liver.

Authors:  Azza A K El-Sheikh; Rehab A Rifaai
Journal:  PPAR Res       Date:  2014-04-02       Impact factor: 4.964
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.